Detailed information for compound 144211

Basic information

Technical information
  • TDR Targets ID: 144211
  • Name: 1-(1,3-benzothiazol-6-yl)-3-[2-oxo-1-[[3-(pro pan-2-ylcarbamoylamino)phenyl]methyl]-4,5-dih ydro-3H-1-benzazepin-3-yl]urea
  • MW: 542.652 | Formula: C29H30N6O3S
  • H donors: 4 H acceptors: 4 LogP: 4.19 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: CC(NC(=O)Nc1cccc(c1)CN1C(=O)C(CCc2c1cccc2)NC(=O)Nc1ccc2c(c1)scn2)C
  • InChi: 1S/C29H30N6O3S/c1-18(2)31-28(37)32-21-8-5-6-19(14-21)16-35-25-9-4-3-7-20(25)10-12-24(27(35)36)34-29(38)33-22-11-13-23-26(15-22)39-17-30-23/h3-9,11,13-15,17-18,24H,10,12,16H2,1-2H3,(H2,31,32,37)(H2,33,34,38)
  • InChiKey: HOEGWQPGDGZHBS-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 1-(1,3-benzothiazol-6-yl)-3-[1-[[3-(isopropylcarbamoylamino)phenyl]methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 1-(1,3-benzothiazol-6-yl)-3-[1-[[3-[[(isopropylamino)-oxomethyl]amino]phenyl]methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 1-(1,3-benzothiazol-6-yl)-3-[1-[3-(isopropylcarbamoylamino)benzyl]-2-keto-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 3-(1,3-benzothiazol-6-yl)-1-[2-oxo-1-[[3-(propan-2-ylcarbamoylamino)phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 3-(1,3-benzothiazol-6-yl)-1-[1-[[3-(isopropylcarbamoylamino)phenyl]methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 3-(1,3-benzothiazol-6-yl)-1-[1-[[3-[[(isopropylamino)-oxomethyl]amino]phenyl]methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]urea
  • 3-(1,3-benzothiazol-6-yl)-1-[1-[3-(isopropylcarbamoylamino)benzyl]-2-keto-4,5-dihydro-3H-1-benzazepin-3-yl]urea

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens neuropeptide Y receptor Y1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi follicle stimulating hormone receptor neuropeptide Y receptor Y1 384 aa 345 aa 22.0 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi Nuclear hormone receptor family member nhr-25 0.0641 0.2539 1
Onchocerca volvulus Protein ultraspiracle homolog 0.0119 0 0.5
Echinococcus granulosus FTZ F1 nuclear receptor protein 0.0641 0.2539 0.2539
Schistosoma mansoni hypothetical protein 0.0522 0.1962 0.7728
Onchocerca volvulus Bile acid receptor homolog 0.0119 0 0.5
Schistosoma mansoni FTZ-F1 nuclear receptor-like protein 0.0641 0.2539 1
Onchocerca volvulus Steroid hormone receptor family member cnr14 homolog 0.0119 0 0.5
Loa Loa (eye worm) hypothetical protein 0.0641 0.2539 1
Onchocerca volvulus 0.0119 0 0.5
Echinococcus multilocularis FTZ F1 nuclear receptor protein 0.0641 0.2539 1
Brugia malayi Nuclear hormone receptor family member nhr-25 0.0641 0.2539 1
Echinococcus multilocularis FTZ F1 alpha 0.0641 0.2539 1

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = 5.1 nM In vitro binding affinity towards Neuropeptide Y receptor type 1 was determined as potency to displace [125I]-peptide YY binding to human neuroblastoma SK-N-MC cells ChEMBL. 10411482
Ki (binding) = 5.1 nM In vitro binding affinity towards Neuropeptide Y receptor type 1 was determined as potency to displace [125I]-peptide YY binding to human neuroblastoma SK-N-MC cells ChEMBL. 10411482

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.